RAS野生型转移性结直肠癌帕尼单抗一线治疗策略的健康相关生活质量:Valentino研究预设二次分析
本文为Valentino研究的预设二次分析,评估RAS野生型转移性结直肠癌患者接受帕尼单抗为基础一线治疗的生活质量(QoL)。患者报告结局采用EORTC QLQ-C30、QLQ-CR29及EQ-5D问卷,在基线和每8周评估至疾病进展。结果显示含奥沙利铂诱导化疗联合抗EGFR治疗引起短暂显著QoL恶化,诱导后治疗降强度总体带来健康相关QoL恢复,两维持组间无显著差异。
要点
- 含奥沙利铂化疗联合抗EGFR诱导期出现短暂显著QoL下降
- 诱导后降强度治疗总体QoL恢复,并预期减少奥沙利铂相关神经毒性
- 两维持组在24/32/40周各问卷评分变化无显著差异
核心结论
- RAS野生型mCRC患者含奥沙利铂诱导化疗联合抗EGFR引起短暂显著QoL恶化,诱导后治疗降强度总体带来健康相关QoL恢复。
研究设计与样本
- Valentino研究的预设二次分析,患者报告结局采用EORTC QLQ-C30、QLQ-CR29和EQ-5D问卷,基线和每8周评估至疾病进展。
- A组/B组基线问卷完成率分别为91.5%/92.0%。
主要发现
- 两臂在维持期24/32/40周三份问卷的依从性、基线评分及相对基线平均变化均无显著差异。
- 总体人群平均变化显示诱导期早期恶化,维持期部分恢复,涉及整体QoL、功能量表及QLQ-C30的疲乏、恶心/呕吐、食欲丧失、腹泻等症状条目。
- QLQ-CR29的体像、口干、脱发、味觉、大便失禁、皮肤疼痛及EQ-5D视觉模拟量表(VAS)评分亦呈类似变化。
临床怎么用
- 对RAS野生型mCRC患者,含奥沙利铂诱导联合抗EGFR期间应预期短暂QoL下降并进行监测。
- 诱导后治疗降强度可在预期减少奥沙利铂相关神经毒性之外,带来整体健康相关QoL恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quality of life (QoL) patient-reported outcomes (PROs) data from pivotal first-line trials in metastatic colorectal cancer (mCRC) are poor. The Valentino study showed that de-escalation to single-agent panitumumab after 4-month induction with panitumumab-FOLFOX is inferior to panitumumab-5-FU/LV in patients with RAS wild-type mCRC, although slightly reducing toxicity. We report QoL, a secondary end-point. METHODS: PROs were assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30), EORTC QLQ-CR29, EuroQol EQ-5D questionnaires, at baseline and every 8 weeks until disease progression. First two evaluations correspond to induction treatment (identical in both arms), while subsequent to maintenance. To describe QoL changes over time, mean changes from baseline at each time point were calculated in overall population. To compare maintenance between two arms, mean changes and proportion of improved/stable/worse patients versus baseline were compared for each item. RESULTS: In arm A/B, 91.5%/92.0% of enrolled patients completed questionnaires at baseline. No significant differences in the two arms were reported in compliance, baseline scores and mean changes versus baseline for the three questionnaires during maintenance (24/32/40 weeks). Overall, mean changes versus baseline showed an early deterioration during induction with partial recovering during maintenance for global QoL, functional scales and several symptoms/items of QLQ-C30 (fatigue, nausea/vomiting, appetite loss, diarrhoea) and QLQ-CR29 (body image, dry mouth, hair loss, taste, faecal incontinence, sore skin), and EQ-5D Visual Analogue Scale (VAS) score. CONCLUSION: In patients with RAS wild-type mCRC, induction with oxaliplatin-containing chemotherapy plus anti-EGFRs induces a transient significant QoL deterioration. After induction phase, treatment deintensification determines an overall recovery of health-related QoL, besides the expected prevention of oxaliplatin-related neurotoxicity.
引用
- Raimondi A, Di Maio M, Morano F, et al. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. Eur J Cancer. 2020. PMID: 32623288. doi:10.1016/j.ejca.2020.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。